Cell-based therapy for muscular dystrophies was initiated in humans after promising results obtained in murine models. Early trials failed to show substantial clinical benefit, sending researchers back to the bench, which led to the discovery of many hurdles as well as many new venues to optimize this therapeutic strategy. In this review we summarize recent progresses in pre-clinical cell therapy approaches, with a special emphasis on human cells potentially attractive for human clinical trials. Future perspectives for cell therapy in skeletal muscle are discussed, including the perspective of combined therapeutic approaches. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. Concerning the route of administration, at least two ways have been explored, intra-muscular or systemic delivery. Intra-muscular injection has been widely used for SC, and seems appropriate if the target is limited. For a broader distribution to the whole body or a range of muscles, systemic or loco-regional delivery via the blood flow is more adapted. This requires that therapeutic cells can extravasate and be distributed within the target tissue. Different criteria for an ideal cell candidate for muscle cell therapy have been identified. An ideal cell has first to harbour a stable myogenic potential: able to fuse with host myofibers after transplantation, the therapeutic cell will synthesize donor-derived proteins; its colonization of the host SC niche will extend the therapeutic effect, since the donor cell will then be able to participate to new cycles of muscle degeneration/regeneration. This stable myogenic profile is essential in order to avoid differentiation into an inappropriate cell type/tissue. A sufficient number of cells, an easy isolation and amplification are three additional properties required for the ideal cell candidate to be used in clinical GMP conditions. If the candidate cell is compatible with a systemic or loco-regional route of administration, homing capacities to the site of muscle regeneration is also highly required. Finally, if autologous cell therapy is This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Skeletal muscle is the most abundant human tissue. It is a highly specialized post-mitotic tissue assuring many physiological functions including locomotion, maintenance of posture, as well as metabolic activity. Skeletal muscle is also a dynamic tissue retaining a remarkable capacity to adapt to physiological demands such as growth and exercise, and to repair and regenerate following injury or disease 4 . This ability is due to the presence of resident 
Cell-mediated strategies for muscle diseases
Muscular dystrophies (MD) are a heterogeneous group of disorders, characterized by progressive muscle wasting and weakness, with a wide clinical presentation and severity 10 .
More than 30 genetically distinct types of MD have been identified 11, 12 according to the age of onset (paediatric or adults), severity, mode of inheritance, rate of progression, prognosis and the specific muscle groups initially affected. MD are caused by mutations in genes encoding a broad range of proteins located in the extracellular matrix (ECM), at the plasma membrane, in the cytoplasm, at the sarcomere, and in the nucleus of striated muscle cells (http://www.musclegenetable.fr/). Although for many of these MD the genetic defect is now identified and considerable progresses have been made to increase our understanding of muscle genetics, pathophysiology and molecular/cellular partners involved in these pathologies, the pathophysiological mechanisms leading from the genetic mutation to the development of the dystrophic features are still often unknown with no cure available. Several therapeutic strategies have been investigated, including pharmacological, gene-based and cellbased approaches (for pharmacological and gene therapy approaches we suggest to the readers several reviews [13] [14] [15] [16] [17] [18] ). Cell therapy for MD is based on the delivery of precursor cells This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. Concerning the route of administration, at least two ways have been explored, intra-muscular or systemic delivery. Intra-muscular injection has been widely used for SC, and seems appropriate if the target is limited. For a broader distribution to the whole body or a range of muscles, systemic or loco-regional delivery via the blood flow is more adapted. This requires that therapeutic cells can extravasate and be distributed within the target tissue. Different criteria for an ideal cell candidate for muscle cell therapy have been identified. An ideal cell has first to harbour a stable myogenic potential: able to fuse with host myofibers after transplantation, the therapeutic cell will synthesize donor-derived proteins; its colonization of the host SC niche will extend the therapeutic effect, since the donor cell will then be able to participate to new cycles of muscle degeneration/regeneration. This stable myogenic profile is essential in order to avoid differentiation into an inappropriate cell type/tissue. A sufficient number of cells, an easy isolation and amplification are three additional properties required for the ideal cell candidate to be used in clinical GMP conditions. If the candidate cell is compatible with a systemic or loco-regional route of administration, homing capacities to the site of muscle regeneration is also highly required. Finally, if autologous cell therapy is 8, 19, 25 . Immunosuppression of patients, low migration and poor survival of human injected myoblasts were parameters that began to be taken into account 19, 26, 27 . Since then, several research groups started to develop xenotransplantation strategies in immunodeficient preclinical mouse models in order to analyse human myoblast behaviour and the regulation of key biological events occurring in the host muscle after intramuscular myoblast transplantation in order to design rational strategies to improve grafting [28] [29] [30] . For example, we showed that human myoblasts do not disappear massively during the first days after injection This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
as previously described for mouse myoblast injection 31 . A significant portion of grafted human myoblasts survives and engrafts host muscle, although a cell death peak (occurring 12-24 hours following transplantation) is noted ( 32 and unpublished data). Interestingly, we observed an in situ proliferation of human myoblasts during the first three days post transplantation that was able to compensate the loss of cells occurring after injection 32 .
Preclinical studies have pointed out a poor migration of engrafted myoblasts in both mouse 33, 34 and monkey 35 muscles, although some migration has been detected in more recent studies in nonhuman primates 36 . Interestingly, we have shown that the migration of the grafted human myoblasts is limited to the first 3 days after transplantation, then proliferation is down-regulated and grafted myoblasts start to differentiate in situ, suggesting that proliferation, migration and differentiation are tightly linked and that modifying one of these three processes has an impact on the others 32 . In preclinical models, muscle damage or were based on these settings. Such of protocol remains applicable to small and accessible muscles in DMD patients or in the context of autologous myoblast transplantation for localized muscles in less extended diseases such as OPMD, but seems inappropriate to treat numerous large targets.
Other myogenic stem cells
Myoblasts are often exhausted in dystrophic conditions (such as DMD) 40 , which hampers their isolation, modification and amplification for autografts. Furthermore, myoblasts, whatever their origin, cannot be injected systemically, which is the ideal route to target large amounts of tissue 41, 42 . These reasons have encouraged the investigation and the identification This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
from different origin, i.e. skeletal muscle for MuStem and muscle blood vessels for mesoangioblasts, and with different methods, common phenotypic properties, such as multilineage potential and homing to damaged muscle when injected systemically (see Table   1 ), may suggest some similarities between these two types of myogenic cells. Further studies to characterize MuStem cells in terms of heterogeneity and regenerative potential are needed before they can be considered for therapeutic application.
Clinical trial: the example of a phase I/IIa study of autologous myoblast cell transplantation for OPMD Intramuscular injections of myoblasts -despite their reduced proliferative capacity and migration -always lead to localized tissue repair at the site of injection 25 . OPMD appears as an ideal situation where myoblast transplantation is applicable. Indeed, OPMD is a late-onset autosomal dominant slow progressing inherited dystrophy caused by an abnormal trinucleotide repeat expansion in the PABPN1 gene 55, 56 , where a small group of specific muscles (eyelid and pharyngeal) are primarily affected, leading to both ptosis and dysphagia.
Affected cricopharyngeal muscle is characterized by exacerbated fibrosis and atrophy 57 .
Surgical correction for eyelid and pharyngeal muscle weakness are to date the only therapy to increase the quality of life of these OPMD patients. However surgical myotomy (to fight dysphagia) provides in most cases only a transient benefit with a secondary progressive reoccurrence of dysphagia a few years later 58 . A few years ago, we demonstrated that myoblasts isolated from clinically unaffected muscles of OPMD patients had a normal proliferation and differentiation capacity 59 suggesting that an autologous transplantation of myoblasts isolated from clinically unaffected muscles and implanted into affected pharyngeal muscles may improve their motility and restore some muscle function. A preclinical study in dog confirmed the feasibility of such a protocol 59 . A phase I/IIa clinical study tolerance of the procedure with no adverse side effects. A cell dose dependant functional improvement in swallowing was even observed in this safety study 60 . This study is now being extended to 12 new patients, including patients without a myotomy to decipher the respective contribution of the myoblast injection and the myotomy.
Cell therapy: future perspectives

Improving therapeutic potential of myoblast cell therapy
It is now confirmed that culture conditions modify transplantation efficiency of muscle progenitors: mouse myoblasts are less efficient than the SC they are derived from 61 or even less than the initial SC in its niche 62 and this is probably also true for human cells. Although freshly isolated SC present a high regenerative potential, they will probably not be a therapeutic option because of their limited number. Identifying the modifications arising during the expansion of myoblasts would allow the identification of optimized conditions to improve the regenerative potential of amplified myoblasts. As an example, it has been recently shown that inhibition of p38 signalling pathway during human myoblast expansion in vitro greatly enhances their engraftment in vivo 63 .
Regarding the niche, the importance of the physiological rigidity of substrates used in vitro on the control of stem cell fate has been documented 64 This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
conditions of culture result in an increased engraftment ability of these cells when injected in vivo in regenerating muscles 65 . Recently, Yennek et al using micropatterns coated with ECM proposed that geometry micropattern plays a predominant effect on the fate of the dividing cells 66 . All these approaches have been tested on myoblasts, but substrate rigidity is known to modify the fate of other stem cells 64 . Although these approaches cannot yet be applied in clinical conditions for various reasons (cost, complexity, scale-up), the involved parameters, from the modulation of signalling to optimization of the substrates, will have to be taken into account for the optimization of large-scale cell cultures for future therapeutic use of stem cells in clinical trials.
Fibrotic environment
If elasticity plays a key role in the SC fate ex vivo, it should also be taken into account in vivo:
transplanting cells in a stiffer environment may modify their behaviour. Studies of muscle fibre rigidity in the mdx mouse showed that dystrophic fibres are more rigid than wild-type, probably du to the absence of dystrophin 67 This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
they may play an active role during muscle regeneration 73, 74 and/or in the installation of the fibrosis associated with ECM deposition in the dystrophic mouse model mdx 75 . If the presence of FAPs is confirmed in humans, it will be essential to decipher their influence on regeneration, their potential cross-talk with SC and characterize their role in fibrogenesis to ameliorate muscle cell therapy. Indeed muscular fibrosis hampers the success of gene or cell therapy at advanced stages of the disease 78 , and pre-anti-fibrotic treatment using tendon modified fibroblasts (expressing angiogenic factors and metalloproteinase) that can restore microcirculation and reduce connective tissue deposition in aged dystrophic mice could ameliorate muscle tissues in patients at advanced stages of the disease 76 . Although it is not yet known how deregulation of ECM components (proteins, glycoproteins, glycosaminoglycans, etc) contribute to worsening of the disease and participate in the formation of fibrosis, improve quality of receiver muscle with anti-fibrotic therapies before receiving the graft will certainly be essential to optimize implanted cell fate in cell therapy.
Human Embryonic and induced pluripotent stem cells: future candidate cells?
Much energy has been put in the last years to increase the myogenic commitment of human pluripotent stem cells embryonic stem cells (hES) 77 and induced pluripotent stem cells (iPS) 78, 79 . Human ES cells are isolated from the early embryo (5-6 days) and have the potential to differentiate into all tissues of the three germ layers. Generation and use of hES cells in therapy poses ethical issues, related to the destruction of human embryo, but also safety issues since hES cells can lead to formation of teratomas if they are not fully differentiated 80 .
Although myogenic hES capable of muscle engraftment have been reported during the past years (for more details see 81 ), most of these strategies used genetic manipulation of hES (lentiviral vector integration,) introducing additional risks, related to the immunogenicity of viral vector proteins and the integration of the transgene in the human genome. Moreover, hES cell-based therapy will have to be an heterologous approach, and the immune privilege of hES cells is today debated 82 since they seem to increase their immunogenicity as they progress towards differentiation 83 .
Generation of iPS cells poses less ethical issues than hES since iPS cells are typically generated from adult somatic cells by reprograming them with a defined and limited set of transcription factors (Oct3/4, Sox2, c-Myc, Klf4). Described first in mouse 78, 79 , this approach is now applied to human somatic cells 84 . Several studies showed that combination of compounds 85 , recombinant proteins fused to cell-penetrating peptide 86 , expression plasmids 87 or microRNA 88 Up to now, no universal cell candidate that could be maintained and amplified in vitro and delivered to patients without immune rejection has been described, and the promises raised by the myogenic potential of hiPS still suggest personalized medical treatment involving the generation of hiPS for each patient. Although costs for curing life threatening diseases such as DMD should be analysed in view of their devastating evolution, patient tailored approaches may be variably accessible depending on the country and national health care organization, representing another kind of ethical concern. Independently of the cell candidate chosen, one This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
solution could be the development of haplobanks matching an as large as possible majority of the population, as suggested for iPS by Wilmut et al in 2015 92 . These haplobanks however will have to be specific for genetically distinct populations, e.g. an ideal haplobank for
Caucasians will be different from that for the Japanese population.
Conclusion
The first demonstration of cell therapy for muscle dystrophy in murine models raised some concern: 1) the cell type, including systemic delivery of myogenic stem cells to reach a larger amount of tissue; 2) the pre-treatment of the targeted tissue to diminish fibrosis and enhance delivery of the therapeutic agent (this is also true for other approaches, including gene therapy); 3) the combination of strategies, e.g. combined gene and cell therapy to deliver corrected autologous cells, or combined cell types that may together enhance repair and/or revascularization ( Fig. 1) . This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
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